dr. david gandara discusses multiplexing molecular tests for nsclc
Published 12 years ago • 115 plays • Length 2:03Download video MP4
Download video MP3
Similar videos
-
1:34
dr. david gandara on patient selection for molecular testing in lung cancer
-
1:20
dr. david gandara describes exciting new lung cancer research
-
2:53
dr gandara: perspective on tissue acquisition in mnsclc
-
1:02
david gandara, md, current thinking regarding testing for pd-l1 biomarker in nsclc patients
-
1:16
dr. gandara discusses clinical implications of the flaura study in nsclc
-
1:36
dr. david gandara on thymidylate synthase expression in alk-positive non-small cell lung cancer
-
5:40
concurrent versus sequential testing in nsclc
-
0:53
dr. gandara on measuring tmb in nsclc
-
57:36
high-throughput genomics in cancer immunity and immunotherapy by dr. ansuman satpathy
-
41:25
human immune system reconstituted ncg models for immunotherapy
-
7:21
histopathology lung-- adenocarcinoma
-
3:10
dr gandara: the role of the multidisciplinary team in molecular testing
-
1:02
dr. gandara on the mystic trial for lung cancer
-
1:42
dr. gandara discusses pd-l1 as a biomarker in lung cancer
-
1:40
dr. gandara discusses the oak trial for lung cancer
-
5:58
common mutations in lung cancer
-
2:15
dr. gandara on practice-changing studies in lung cancer
-
14:52
the lung cancer living room™ - your molecular fingerprint - david gandara, md - nov. 2011
-
3:30
the cost-effectiveness of targeted therapies in nsclc
-
0:58
dr. david gandara spotlights the giants of cancer care
-
1:55
dr. gandara on the impact of immunotherapy on the tumor microenvironment in lung cancer
-
0:58
david gandara, md,, discusses pd-l1 expression and selecting the appropriate agent in nsclc patients